The European Anchor of Vaccine CDMO: Two Years After Buying IDT, SK bioscience Has Turned Public Procurement into Orders

A regulatory filing disclosed by SK bioscience on 25 October shows 2025 consolidated revenue of KRW 651.4 billion (+143.5%) and an operating loss narrowed to KRW 123.5 billion. Acquired German CDMO IDT Biologika posted H1 2026 revenue of KRW 257.8 billion and operating profit of KRW 127 billion, already above all of 2025. The company targets doubling IDT's revenue by 2028, using an EU HaDEA microneedle patch framework worth up to EUR 225 million and a CEPI-funded Ebola project.

On 25 October a regulatory filing to Korea's Financial Supervisory Service disclosed a set of numbers for SK bioscience: 2025 consolidated revenue of KRW 651.4 billion (about USD 450 million), up 143.5% year on year, and an operating loss narrowed from KRW 138.4 billion to KRW 123.5 billion. The revenue more than doubling is directly attributable to the October 2024 acquisition of roughly 60% of German vaccine CDMO IDT Biologika.

The more interesting line is the acquired asset's trajectory. Founded in 1921, IDT handles both drug substance and fill-finish for vaccines and biologics. It posted full-year 2025 revenue of KRW 465.7 billion and operating profit of KRW 9.9 billion; in the first half of 2026 it reported revenue of KRW 257.8 billion and operating profit of KRW 12.7 billion — six months of profit already exceeding all of 2025.

That is the plainest test of whether a cross-border CDMO acquisition works: the acquired asset turns profitable in year one and accelerates in year two. SK bioscience's stated target is to double IDT's revenue from the level at acquisition by 2028.

Vaccine CDMO and antibody CDMO are two different businesses

Set SK and IDT beside Samsung Biologics and Lonza and the word CDMO conceals two entirely different capacity economics.

Antibody CDMO is about scale: 2,000 to 20,000 litre mammalian cell culture batches, with cost diluted through reactor litres, batch counts and utilisation. Competition is over who has more litres and more lines cleared by regulators. Samsung Biologics at 845,000 litres and Lonza at 793,000 litres are products of that logic.

Vaccine CDMO is about small batches, many products and heavy regulation. A vaccine programme often involves multiple antigens, adjuvants and presentations, with batch sizes far below antibodies, but requires BSL-2/BSL-3 containment, dedicated adjuvant and filling lines, and navigation of divergent regulatory paths such as batch release in China or centralised EMA review in Europe. Scarcity is not in litres but in the combined qualification to handle live virus, adjuvants and sterile fill-finish under one roof.

IDT sits precisely on that combined qualification: drug substance and fill-finish, commercial batches and public health programmes. Few such European assets exist, and new builds are slow and approval-heavy — which is why SK bioscience moved in 2024.

Public procurement: an underrated demand channel

The strategic value of the deal shows up in two concrete programmes.

The first is a microneedle patch influenza vaccine. The project is led by the EU's Health and Digital Executive Agency (HaDEA), with Australia's Vaxxas supplying microarray patch technology and manufacturing, SK bioscience supplying cell culture-based seasonal and pandemic influenza drug substance, and IDT handling European contracts and project management, potentially taking on drug substance production at commercialisation. Phase one, including a Phase 1 trial, is worth up to EUR 12.9 million (about KRW 19.2 billion), and three related framework contracts could grow to a combined EUR 225 million (about KRW 334.2 billion).

The second is an Ebola vaccine. SK bioscience and IDT are participating alongside Merck and Hilleman Laboratories in a Zaire Ebola vaccine project, with CEPI providing Merck up to USD 30 million. SK bioscience handles process development and manufacturing of drug substance; IDT handles development and production of the finished product.

These two programmes reveal the biggest business-model difference from antibody CDMO: the largest customers of vaccine CDMOs are governments and public funds, not pharmaceutical companies. HaDEA and CEPI framework contracts share three features — multi-year terms, prepayment, and pricing based on reserved capacity rather than batches purchased. For the CDMO this is more stable cash flow than commercial orders; for the buyer it is the only way to guarantee capacity is available in a pandemic.

That also explains why not all pandemic-era vaccine capacity went idle afterwards: some of it converted into public health capacity reserves, kept at minimum utilisation through framework contracts from bodies such as CEPI, BARDA and HaDEA. This demand curve is unrelated to pharma R&D budgets and closely tied to geopolitics and biosecurity agendas.

The tariff identity of European capacity

There is a less visible but very practical layer: origin.

US Section 232 pharmaceutical tariffs took full effect on 29 September 2026, with a 100% base rate on patented drugs, APIs and key starting materials, and an agreed 15% rate for the EU, Japan, Korea and Switzerland, and 10% for the UK. For any CDMO serving the US market, European capacity and Asian capacity are two different prices in tariff terms.

IDT's site in Dessau, Germany, has both drug substance and fill-finish capability, which lets SK bioscience offer US clients an all-European substance-plus-fill package rather than shipping intermediates across borders and paying duty twice. For vaccines, sensitive to cold chain and release timelines, an end-to-end single origin carries additional quality advantages.

Korean capacity plays a different role: the Songdo site serves the company's own vaccines and Asian supply, while the German site serves European and US commercial supply. The filing describes a product-by-product sequence of technology transfer, process validation and regulatory steps, producing a two-base structure of Korea plus Germany.

Korea's CDMO division of labour has taken shape

Line up Korea's three main players and a fairly clear division appears: Samsung Biologics in antibodies and ADCs (Songdo plants 1 to 5 plus Rockville, with total capacity planned to 1.385 million litres); SK bioscience in vaccines (Korea plus Germany); ST Pharm in oligonucleotides. All three are export and large-client businesses, but their modalities do not overlap.

This division was not designed so much as forced by order structure. Samsung's clients are MNC antibody pipelines, SK's clients are governments and public funds, ST Pharm's clients are siRNA and new nucleic acid developers. The three purchasing logics are entirely different — capacity qualification, framework reservation, and process capability respectively.

The reference point for Chinese CDMOs is that vaccine CDMO remains a segment where Chinese participation is low and the barrier is qualification rather than capacity. Domestic vaccine production centres on batch release; going abroad requires WHO prequalification first, then entry into public procurement chains such as UNICEF, PAHO and CEPI. The path is slow, but once inside, order continuity and margins beat price competition on commercial batches.

Editor's view: the third, overlooked demand curve

The two CDMO demand curves discussed all year are GLP-1 peptides and ADCs. The SK and IDT story points to a third: public health capacity reserves. It is smaller than the other two, but structurally different — it is not triggered by a product launch, not priced by negotiation, and inherently multi-year, reservation-based and geopolitically anchored.

In a year when Section 232 tariffs have turned origin into a quotation variable, the value of this demand is amplified: whoever holds capacity certified by public bodies and located in a preferential tariff jurisdiction holds two tickets at once — one for orders, one for tariff identity. IDT's German site is exactly such a ticket.

The caution for investors is to look past headline contract value to reserved capacity and minimum purchase commitments. The former is intent; the latter is revenue. The EUR 225 million SK bioscience disclosed is the combined ceiling of three framework contracts, and actual execution depends on public health demand and regulatory timing — a discount that belongs in any valuation.